The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
Men and women ≥ 18 years of age.
Patients must have histologic confirmation of Follicular Lymphoma (FL) (grade 1, 2 and 3A). Note: Participants who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy.
Patients with relapsed or refractory FL previously treated with ≥1 line of systemic therapy having ≥ 1 Groupe d'Etude des Lymphomes (GELF) criteria for therapy, or Progression of Diseases within 24 months (POD24), or second relapse.
Baseline FDG-PET/CT scans must demonstrate positive lesions compatible with CT defined anatomical tumor sites. Patients should have at least one measurable site of disease per Lugano classification.
FL grade 3B or transformed FL.
[Removed]
≥ 6 lines of systemic immunochemotherapy for treatment of FL.
Patients with clinically significant pleural effusions and/or ascites requiring drainage or associated with shortness of breath.
Juan P. Alderuccio, MD
Lead sponsor
University of Miami
Sponsor institution
ADC Therapeutics S.A.
Collaborator